FDA approves labeling changes for over-the-counter (OTC) weight loss drug alli (orlistat) to warn of risk of kidney stones and kidney injury
Pending the results of the FOCUS Trial and other future studies, how should optometrists approach diabetic patients who go on a GLP-1/GIP agonist
Over the 5-year follow-up, there was an all-cause increased mortality risk of 1.29-fold vs the normokalemia cohort (45% vs 37%), a 1.40-fold increased risk for major adverse cardiac events (MACEs) (60% vs 45%), a risk of 1.72 (34% vs 19%) for RAASi discontinuation, and a 1.94-fold higher risk of hospitalization with arrhythmia compared with the matched normokalemia cohort [20]
But whether theyre right for you depends on your health history, your goals, and what your licensed healthcare provider recommends
PubMed evidence trail Research sources used to frame this page For NAD+ With Tirzepatide Combination Guide, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available
While uncommon, these symptoms require urgent assessment to rule out heart failure or kidney impairment